



**MONOSPECIFIC ANTI-HUMAN GLOBULIN REAGENT (RABBIT)
DIRECTIONS FOR USE**

Monospecific Anti-Human IgG (Clear or Green): For Antiglobulin Techniques.

SUMMARY

In 1945, Coombs, Mourant and Race described the use of anti-human globulin serum for detecting red cell-bound non-agglutinating antibodies.

PRINCIPLE

When used by recommended techniques, the reagent will cause agglutination (clumping) of red cells, carrying IgG, in the antiglobulin phase of testing. No agglutination usually indicates the absence of IgG (See **Limitations**).

REAGENTS

Lorne Monospecific Anti-Human IgG Clear and Anti-Human IgG Green reagents contain anti-IgG derived from rabbits. All non-specific activity is removed by absorption. The reagents are supplied at optimal dilution, for use with all the recommended techniques stated below without the need for further dilution or addition. For lot reference number and expiry date see **Vial Label**.

Reagent	Colour	Dye Used
Anti-Human IgG Clear	Colourless	None
Anti-Human IgG Green	Green	Patent Blue and Tartrazine

STORAGE

Do not freeze. Reagent vials should be stored at 2 - 8°C on receipt. Prolonged storage at temperatures outside this range may result in accelerated loss of reagent reactivity.

SAMPLE COLLECTION AND PREPARATION

Samples should be drawn aseptically into EDTA and tested within 24 hours. If EDTA is unavailable, samples drawn into ACD, CPD or CPDA-1 are preferable to clotted ones. If only clotted samples are available, do not refrigerate them before testing. All blood samples should be washed at least twice with PBS before being tested.

PRECAUTIONS

1. The reagents are intended for *in vitro* diagnostic use only.
2. If a reagent vial is cracked or leaking, discard the contents immediately.
3. Do not use the reagents past the expiration date (see **Vial Label**).
4. Do not use the reagents if a precipitate is present.
5. Protective clothing should be worn when handling the reagents, such as disposable gloves and a laboratory coat.
6. The reagents have been filtered through a 0.2 µm capsule to reduce the bio-burden. Once a vial has been opened the contents should remain viable up until the expiry date as long as there is no marked turbidity, which can indicate reagent deterioration or contamination.
7. The reagents contain < 0.1% sodium azide. Sodium azide may be toxic if ingested and may react with lead and copper plumbing to form explosive metal azides. On disposal flush away with large volumes of water.
8. Materials used to produce the products were tested at source and found to be negative for HIV 1+2 and HCV antibodies and HBsAg using approved microbiological tests.
9. No known tests can guarantee that products derived from human or animal sources are free from infectious agents. Care must be taken in the use and disposal of each vial and its contents.

DISPOSAL OF REAGENT AND DEALING WITH SPILLAGES

For information on disposal of the reagents and decontamination of a spillage site see **Material Safety Data Sheets**, available on request.

CONTROLS AND ADVICE

1. It is recommended a positive control (weak Anti-D 0.1 IU/ml) and a negative control (an inert serum) be test in parallel with each batch of tests. Tests must be considered invalid if controls do not show expected results.
2. The antiglobulin techniques can only be considered valid if all negative tests react positively with IgG sensitised red cells.
3. In the **Recommended Techniques** one volume is approximately 40µl when using the vial dropper provided.
4. The use of the reagents and the interpretation of results must be carried out by properly trained and qualified personnel in accordance with the requirements of the country where the reagents are in use.
5. The user must determine the suitability of the reagents for use in other techniques.

REAGENTS AND MATERIALS REQUIRED

- Coombs cell washer.
- Glass test tubes (10 x 75 mm or 12 x 75 mm).
- IgG sensitised red cells i.e. Lorne Coombs Control Cells (Cat # 970010).
- Inert antibody i.e. Lorne Inert AB Serum (Cat # 110010).
- Low Ionic Strength Solution (LISS): Containing 0.03M NaCl, 0.003M Na₂HPO₄; NaH₂PO₄ buffer pH 6.7 at 22°C ± 1°C and 0.24M glycine.
- Phosphate Buffered Saline (PBS): NaCl 0.9%, pH 7.0 ± 0.2 at 22°C ± 1°C.
- Volumetric pipettes.
- Water bath or dry heat incubator equilibrated to 37°C ± 2°C.
- Weak anti-D i.e. Lorne Precise Weak Anti-D (Cat # 209005).

RECOMMENDED TECHNIQUES

A. Direct Antiglobulin Technique (DAT)

1. Wash test red cells 4 times with PBS, taking care to decant saline between washes and resuspend each cell button after each wash. Completely decant saline after last wash.
2. Add 2 volumes of Lorne Anti-IgG to each dry cell button.
3. Mix thoroughly and centrifuge all tubes for 20 seconds at 1000 rcf or for a suitable alternative time and force.
4. Gently resuspend red cell button and read macroscopically for agglutination

B. Indirect Antiglobulin Technique (NISS IAT)

1. Prepare a 2-3% suspension of washed test red cells in PBS.
2. Place in a labelled test tube: 2 volumes of test serum and 1 volume of test red cell suspension.
3. Mix thoroughly and incubate at 37°C for 15 minutes.
4. Wash test red cells 4 times with PBS, taking care to decant saline between washes and resuspend each red cell button after each wash. Completely decant saline after last wash.
5. Add 2 volumes of Lorne Anti-IgG to each dry cell button.
6. Mix thoroughly and centrifuge all tubes for 20 seconds at 1000 rcf or for a suitable alternative time and force.
7. Gently resuspend red cell button and read macroscopically for agglutination

C. LISS Indirect Antiglobulin Technique (LISS IAT)

1. Prepare a 1.5-2% suspension of washed test red cells in LISS.
2. Place in a labelled test tube: 2 volumes of test serum and 2 volumes of test red cell suspension.
3. Mix thoroughly and incubate at 37°C for 15 minutes.
4. Follow steps 4 to 7 of **NISS IAT** above.

INTERPRETATION OF TEST RESULTS

1. **Positive:** Agglutination of test red cells constitutes a positive test result and within the accepted limitations of the test procedure, indicates the presence of IgG on the test red cells.
2. **Negative:** No agglutination of the test red cells constitutes a negative result and within the accepted limitations of the test procedure, indicates the absence of IgG on the test red cells.

STABILITY OF THE REACTIONS

1. Washing steps should be completed without interruption and tests centrifuged and read immediately after addition of the reagent. Delays may result in dissociation of antigen-antibody complexes, causing false negative or weak positive results.
2. Caution should be exercised in the interpretation of results of tests performed at temperatures other than those **recommended**.

LIMITATIONS

1. Red cells that have a positive DAT due to a coating of IgG cannot be typed by the **Indirect Antiglobulin Techniques**.
2. Inadequate washing of red cells in the indirect antiglobulin technique may result in neutralisation of the anti-human globulin reagent.
3. A positive DAT due to complement sensitisation may not reflect *in vivo* complement fixation if test cells are from a refrigerated clotted sample.
4. A negative direct antiglobulin test result does not necessarily preclude clinical diagnosis of ABO Haemolytic Disease of the Newborn or Auto Immune Haemolytic Anaemia. It also does not necessarily rule out HDN, especially if ABO incompatibility is suspected.
5. False positive or false negative results may also occur due to:
 - Contamination of test materials
 - Improper storage, cell concentration, incubation time or temperature
 - Improper or excessive centrifugation
 - Deviation from the recommended techniques

SPECIFIC PERFORMANCE CHARACTERISTICS

- The reagents have been characterised by the procedures mentioned in the **Recommended Techniques**.
- Prior to release, each lot of Lorne Anti-Human IgG Clear and Anti-Human IgG Green is tested by the **Recommended Techniques** against red cells coated with Anti-D, Anti-K and Anti-Fy^a to check suitable reactivity.
- The anti-IgG potency has been tested against the following minimum potency reference standard obtained from National Institute of Biological Standards and Controls (NIBSC):
 - Anti-AHG reference standard 96/666
- The reactivity of any Anti-IgM, Anti-IgA or Anti-light chain components that might be present has not been established.
- The Quality Control of the reagents was performed using red cells that had been washed with PBS prior to use.
- The reagents comply with the recommendations contained in the latest issue of the Guidelines for the UK Blood Transfusion Services.

DISCLAIMER

- The user is responsible for the performance of the reagents by any method other than those mentioned in the **Recommended Techniques**.
- Any deviations from the **Recommended Techniques** should be validated prior to use⁶.

BIBLIOGRAPHY








- Coombs RRA, Mourant AE, Race RR. A new test for the detection of weak and "incomplete" Rh antibodies. *Brit J Exp Pathol*. 1945; 26:255.
- Wright MS, Issitt PD. Anti-complement and the indirect antiglobulin test. *Transfusion* 1979; 19:688-694.
- Howard JE, Winn LC, Gottlieb CE, Grumet FC, Garratty G, Petz LD. Clinical significance of the anti-complement components of anti-globulin antisera. *Transfusion* 1982; 22:269.
- Howell P, Giles CM. A detailed serological study of five anti-Jk^a sera reacting by the antiglobulin technique. *Vox Sang*. 1983; 45: 129-138.
- Issitt PD, Smith TR. Evaluation of antiglobulin reagents. A seminar on performance evaluation. Washington, DC. American Association of Blood Banks. 1976; 25-73.
- The Department of Health and Social Security. Health Services Management Antiglobulin Test. False negative results, HN (Hazard) (83) 625 Nov 1983.
- Bruce M, Watt AH, Hare W, Blue A, Mitchell R. A serious source of error in antiglobulin testing. *Transfusion* 1986; 26: 177-181.
- The anti-complement reactivity low ionic methods as published by FDA. Recommended Methods for Anti-Human Globulin Evaluation (revision October 1984).
- Dynan PK. Evaluation of commercially available low ionic strength salt (LISS) solutions. *Med Lab Sci* (1981) 381: 13-20.
- Voak D, Downie DM, Moore BPL, Ford DS, Engelfreit CP, Case J. Replicate tests for the detection and correction of errors in anti-human globulin (AHG) tests: optimum conditions and quality control. *Haematologia* 1988; 21(1): 3-16.
- Guidelines for the Blood Transfusion Service in the United Kingdom. H.M.S.O. Current Edition.
- British Committee for Standards in Haematology, Blood Transfusion Task Force. Recommendations for evaluation, validation and implementation of new techniques for blood grouping, antibody screening and cross matching. *Transfusion Medicine*, 1995, 5, 145-150.

AVAILABLE REAGENT SIZES

	Vial Size	Catalogue Number
Lorne Anti-Human IgG (Clear)	10 ml	401010
	1000 ml	401000
Lorne Anti-Human IgG (Green)	10 ml	402010
	1000 ml	402000

Lorne Laboratories Limited
 Unit 1 Danehill
 Cutbush Park Industrial Estate
 Lower Earley, Reading,
 Berkshire, RG6 4UT
 England
 Tel: +44 (0) 118 921 2264
 Fax: +44 (0) 118 986 4518
 E-mail: info@lornelabs.com

TABLE OF SYMBOLS

	Batch Number		<i>In-vitro</i> Diagnostic
	Catalogue Reference		Store At
	Expiry Date		Manufacturer
	Read Pack Insert		